MY004567 tablets was clinically approved by FDS
Createrna received clinical trial approval from the U.S. Food and Drug Administration (FDA) this month for the treatment of rheumatoid arthritis, following its approval in June from the China Drug Administration's Center for Drug Review (CDE) for the innovative drug MY004567.
MY004567 is an innovative drug with intellectual property rights independently designed and developed by the company. It is the first successful clinical approval project of the company in China and the United States at the same time, indicating that the company's innovative drug research and development capability has initially reached the international research and development level. In the future, the company will actively promote the product to carry out clinical trials in China, the United States and other places, which will help to improve the level and speed of product research and development, and also help to expand the international market and boost the process of enterprise internationalization.
In the future, the company will further enhance its innovative research and development strength, and strive to realize more original drugs in international clinical trials, so that Chinese innovative drugs benefit more global patients.
2023-09-28Createrna Receives Capital Injection from Well-known Investment Institutions
2023-06-25Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan
2022-07-17MY004567 tablets was approved by the FDA US. for clinical trials implied
2022-04-29Dr. Jing Zhang, formerly Head of the Clinical Team at the FDA's Center for Drug Approval, serves as CMO of Createrna